Staar Surgical's ICL
This article was originally published in The Gray Sheet
Executive Summary
Start of Phase II trials of the implantable contact lens for hyperopia (farsightedness) is announced by the company March 25. FDA's approval allows the company to expand its investigator base from four to 10 surgeons and to implant 62 ICLs in patients. A Phase I hyperopia trial conducted outside the U.S. included 10 patients with an average preoperative hyperopia of 6.05 diopters. Results showed seven of the ten patients with 20/20 vision or better without glasses or contact lenses and all 10 had 20/40 or better following the procedure, the company claims. Placed in the eye during a suture-less outpatient procedure, the ICL is currently in Phase II trials for myopia. The company hopes to commence Phase III of that trial in the near future. The company received CE mark approval for the ICL in July
You may also be interested in...
COVID-19 Vaccines Donated To Philippines Require Emergency Use Authorization
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: